1113 related articles for article (PubMed ID: 18440643)
1. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.
Yazdani S; Hendi K; Pakravan M; Mahdavi M; Yaseri M
J Glaucoma; 2009; 18(8):632-7. PubMed ID: 19826393
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Sasamoto Y; Oshima Y; Miki A; Wakabayashi T; Song D; Matsushita K; Hamasaki T; Nishida K
J Ocul Pharmacol Ther; 2012 Feb; 28(1):41-8. PubMed ID: 21992534
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.
Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ
Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab as adjuvant for neovascular glaucoma.
Beutel J; Peters S; Lüke M; Aisenbrey S; Szurman P; Spitzer MS; Yoeruek E; ; Grisanti S
Acta Ophthalmol; 2010 Feb; 88(1):103-9. PubMed ID: 18811641
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Iliev ME; Domig D; Wolf-Schnurrbursch U; Wolf S; Sarra GM
Am J Ophthalmol; 2006 Dec; 142(6):1054-6. PubMed ID: 17157590
[TBL] [Abstract][Full Text] [Related]
8. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.
Duch S; Buchacra O; Milla E; Andreu D; Tellez J
J Glaucoma; 2009 Feb; 18(2):140-3. PubMed ID: 19225351
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma.
Ciftci S; Sakalar YB; Unlu K; Keklikci U; Caca I; Dogan E
Eur J Ophthalmol; 2009; 19(6):1028-33. PubMed ID: 19882572
[TBL] [Abstract][Full Text] [Related]
10. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma.
Takihara Y; Inatani M; Kawaji T; Fukushima M; Iwao K; Iwao M; Tanihara H
J Glaucoma; 2011 Mar; 20(3):196-201. PubMed ID: 20440215
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma.
Chen CH; Lai IC; Wu PC; Chen YJ; Chen YH; Lee JJ; Liu YC; Kuo HK
J Ocul Pharmacol Ther; 2010 Feb; 26(1):111-8. PubMed ID: 20148654
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.
Jiang Y; Liang X; Li X; Tao Y; Wang K
Acta Ophthalmol; 2009 Nov; 87(7):736-40. PubMed ID: 18803622
[TBL] [Abstract][Full Text] [Related]
14. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.
Kitnarong N; Chindasub P; Metheetrairut A
Adv Ther; 2008 May; 25(5):438-43. PubMed ID: 18425438
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.
Eid TM; Radwan A; el-Manawy W; el-Hawary I
Can J Ophthalmol; 2009 Aug; 44(4):451-6. PubMed ID: 19606170
[TBL] [Abstract][Full Text] [Related]
16. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.
Oshima Y; Sakaguchi H; Gomi F; Tano Y
Am J Ophthalmol; 2006 Jul; 142(1):155-8. PubMed ID: 16815267
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.
Saito Y; Higashide T; Takeda H; Ohkubo S; Sugiyama K
Acta Ophthalmol; 2010 Feb; 88(1):96-102. PubMed ID: 19775309
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.
Falavarjani KG; Modarres M; Nazari H
Eye (Lond); 2010 Apr; 24(4):717-9. PubMed ID: 19407842
[TBL] [Abstract][Full Text] [Related]
19. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
20. Role of intravitreal bevacizumab in neovascular glaucoma.
Gheith ME; Siam GA; de Barros DS; Garg SJ; Moster MR
J Ocul Pharmacol Ther; 2007 Oct; 23(5):487-91. PubMed ID: 17900231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
